X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Simvastatin is one of the statins — cholesterol-lowering drugs, which are among the most important medications in cardiovascular prevention. It lowers LDL cholesterol, stabilizes vascular plaques and has been shown to reduce heart attacks and strokes. But simvastatin has a special feature that distinguishes it from other statins: It is heavily metabolized by the liver enzyme CYP3A4 — and it is precisely this enzyme that is blocked by many other drugs. Especially amlodipine: The most common and most overlooked interaction in German pharmacies.
See more detail.gif)
Simvastatin is prescription-only. Never stop it on your own – the heart protection is vital in the long term.
Simvastatin is one of the most prescribed medications worldwide and has been a fixed component of cardiovascular prevention for decades. It belongs to the class of statins – cholesterol reducers that not only lower the LDL level but, through so-called pleiotropic effects, also directly protect the vessel wall. Simvastatin, however, has some pharmacological peculiarities that distinguish it from newer statins: a short half-life (an evening intake is compulsory), a pronounced CYP3A4 dependence (many interactions), and a clinically critical dose limit on amlodipine.
| Property | Details |
|---|---|
| Active substance | Simvastatin |
| ATC code | C10AA01 |
| Substance class | HMG-CoA reductase inhibitor (statin) |
| Available forms | Tablets 10 mg, 20 mg, 40 mg, 80 mg |
| Half-life | 1–3 hours (active metabolites longer) |
| Bioavailability | About 5% (strong first-pass metabolism!) |
| Metabolism | CYP3A4 (very pronounced – the reason for many interactions) |
| Intake time | IN THE EVENING (because of night-time cholesterol synthesis) |
| Prescription status | Yes |
| Special feature | Prodrug – converted in the liver into the active metabolite |
Simvastatin inhibits the enzyme HMG-CoA reductase in the liver – the rate-limiting step of the body's own cholesterol production. When the liver produces less cholesterol, it reacts with a compensatory mechanism: it forms more LDL receptors on its cell surface and takes up more LDL cholesterol from the blood. The LDL level in the blood falls.
Beyond this direct effect, statins have so-called pleiotropic effects: they stabilise vessel-narrowing plaques (which lowers the acute heart attack risk), act anti-inflammatory in the vessel wall, and improve the function of the endothelium. These effects explain why statins can act life-prolonging even with only moderately raised cholesterol.
This is due to the circadian rhythm of cholesterol synthesis: HMG-CoA reductase is most active in the late evening hours and at night – that is the period in which the liver produces the bulk of the daily cholesterol. Simvastatin has a short half-life of only 1–3 hours. When it is taken in the morning, the active substance is already largely broken down in the evening – exactly when the liver produces cholesterol at full speed. An evening intake ensures that simvastatin is present at exactly the right time. This is an important difference from atorvastatin and rosuvastatin, which have long half-lives and can be taken at any time of day.
| Dose | LDL reduction (approx.) | Note |
|---|---|---|
| 10 mg | 27% | Starting dose, e.g. in older patients or with an interaction risk |
| 20 mg | 32% | Standard dose with co-medication with amlodipine |
| 40 mg | 37% | Standard dose without CYP3A4 interactions |
| 80 mg | 42% | Only in patients who have been stable on it without problems for >1 year. New starts not recommended (FDA 2011)! |
This is the clinically most important and most frequently overlooked interaction in simvastatin therapy. It was named "interaction of the year" in 2015 – and is nonetheless still regularly ignored in everyday practice.
The problem in practice: amlodipine and simvastatin are both common cardiovascular medications that are often prescribed together. Many patients have for years taken amlodipine 10 mg and simvastatin 40 mg – without the dose limit being observed. The brite interaction check recognises this constellation automatically.
When 20 mg simvastatin is not enough and amlodipine is to be kept, the solution is not to increase the simvastatin dose – but to switch to another statin. Atorvastatin is influenced only minimally via CYP3A4 (no relevant dose limit on amlodipine), rosuvastatin is not broken down via CYP3A4 at all. Check all combinations in the interaction check.
The amlodipine trap is only the best known among several clinically relevant dose limits. All arise through the same mechanism: inhibition of CYP3A4, the enzyme that breaks down simvastatin.
| Co-medication | Max. simvastatin dose | Reason |
|---|---|---|
| Amlodipine | 20 mg/day | CYP3A4 inhibition → simvastatin level +80% |
| Verapamil | 10 mg/day | Strong CYP3A4 inhibition |
| Diltiazem | 10 mg/day | Strong CYP3A4 inhibition |
| Amiodarone | 20 mg/day | CYP3A4 inhibition |
| Ranolazine | 20 mg/day | CYP3A4 inhibition |
| Grapefruit juice | Avoid! | Inhibits intestinal CYP3A4 massively |
| Ciclosporin | Contraindicated | Extremely increased myopathy risk |
| Gemfibrozil | Contraindicated | Increased rhabdomyolysis risk |
| Clarithromycin / erythromycin | Contraindicated (during antibiotic therapy) | Strong CYP3A4 inhibition → pause simvastatin! |
| Ketoconazole / itraconazole | Contraindicated (during therapy) | Strong CYP3A4 inhibition → pause simvastatin! |
Muscle pain is the best-known side effect of all statins – and the most common reason for a therapy discontinuation. The clinically decisive question is whether the pain means a harmless myalgia or a serious muscle damage. The difference: the CK value in the blood.
| Myalgia (harmless) | Myopathy (serious) | Rhabdomyolysis (an emergency!) | |
|---|---|---|---|
| Frequency | 5–10% of all statin users | <0.1% | <0.01% |
| Symptoms | Muscle pain, stiffness, weakness – WITHOUT a CK rise | Muscle pain + CK >10-fold raised | Extreme muscle breakdown, dark brown urine, kidney failure |
| CK value | Normal | >10× the normal value | Massively raised (often >40×) |
| What to do? | Inform the doctor. Measure CK. A switch to another statin if needed | Stop simvastatin at once! Check CK and kidney values | EMERGENCY – go to hospital at once! |
An important scientific finding that many patients do not know: in controlled studies (the SAMSON study, StatinWISE) patients report similarly frequent muscle pain on a statin and on placebo – when they do not know what they are taking. When patients do know, however, that they are taking a statin, the complaints rise through the nocebo effect (a negative expectation). This does not mean that statin muscle pain is imagined – real myopathies exist. But it means that a CK value should be measured before the statin is stopped. With a normal CK, a re-challenge (a renewed attempt with the same or a lower dose) or a switch to another statin (rosuvastatin, pravastatin) is worthwhile.
